Market Overview

electroCore Announces Third Quarter 2019 Financial Results


Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions

Company to host conference call and webcast today, November 13, at 4:30pm ET

BASKING RIDGE, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine company, today announced third quarter 2019 financial results and provided an operational update.

Third Quarter 2019 and Recent Highlights      

  • Net sales of approximately $683,000, up 10% sequentially from $623,000 in the second quarter
  • 1,736 paid months of therapy in the third quarter of 2019 as compared to 1,023 paid months of therapy in the second quarter and 671 in the first quarter
  • 553 months of paid therapy shipped to VA and DOD facilities during the third quarter, up from 233 months of therapy during the second quarter

"I accepted the CEO role at electroCore because I firmly believe in the potential of the company's novel non-invasive vagus nerve stimulation technology to treat serious headache conditions," said Dan Goldberger, Chief Executive Officer of electroCore. "With FDA-cleared indications for acute treatment of the pain associated with each of migraine and episodic cluster headache, and cluster headache prevention, we have the ability to address significant commercial and government market opportunities that have gone largely untapped to this point. We have a novel, proprietary technology and very large addressable markets, and I, together with the rest of the electroCore team, look forward to unlocking the potential of gammaCore for the benefit of patients as well as our shareholders."  

Third Quarter 2019 Financial Results

For the quarter ended September 30, 2019, electroCore reported net sales of approximately $683,000, compared to $151,000 in the third quarter of 2018. Net sales were $623,000 in the second quarter and $410,000 in the first quarter of 2019. These increases in revenue reflect increased sales in the United States and the United Kingdom. 

Total operating expenses for third quarter of 2019 were approximately $11.2 million, compared to $13.6 million in the third quarter of 2018. The decrease was due primarily to a reduction in SG&A expense, which declined to approximately $8.1 million in the third quarter of 2019 from approximately $11.3 million for the comparable period in 2018, primarily driven by a decrease in compensation and other expenses consistent with the cost reduction plan implemented in June 2019. The third quarter of 2019 included restructuring and other severance related costs of $0.8 million.

GAAP net loss from operations for the third quarter of 2019 was $10.7 million as compared to a loss of $13.2 million in the third quarter of 2018.

Adjusted EBITDA net loss from operations for the third quarter of 2019 was a loss of $8.4 million, a 34% decrease when compared to adjusted EBITDA net loss from operations of $12.7 million for the same period last year.

The Company defines adjusted EBITDA net loss from operations as GAAP net loss from operations, excluding income tax expense, stock-compensation expense, restructuring and other severance related charges, legal fees associated with stockholders litigation and total other income /expense.  A reconciliation of GAAP net loss from operations to Non-GAAP adjusted EBITDA net loss from operations has been provided in the financial statement tables included in this press release.

Cash and cash equivalents and marketable securities at September 30, 2019 totaled approximately $33.5 million, as compared to approximately $68.6 million at December 31, 2018.  Net cash usage for the quarter ended September 30, 2019 was approximately $7.6 million, which included cash outflows of approximately $0.8 million related to severance payments and CEO recruitment costs. By comparison, net cash usage was $11.2 million in the second quarter of 2019 and $16.2 million in the first quarter of 2019.

As previously disclosed, based on its current cash resources, and revenue and expense forecasts, electroCore believes that it will have adequate resources to fund its operations into the beginning of 2021.

Webcast and Conference Call Information

electroCore's management team will host a conference call today beginning at 4:30 p.m. ET. Investors interested in listening to the conference call, or webcast may do so by dialing 877-407-4018 for domestic callers or 201-689-8471 for international callers, using Conference ID: 13695210, or by connecting to the Web:

An archived webcast of the event will be available on the "Investors" section of the Company's website at:

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company's current indications are for the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visit

Forward-Looking Statement

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and product development plans, its expected net cash usage and cash burn rates and liquidity outlook, pipeline or potential markets for its technologies, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents that electroCore files with the SEC available at


Hans Vitzthum
LifeSci Advisors


Media Contact:

Sara Zelkovic
LifeSci Public Relations

electroCore, Inc.
Condensed Consolidated Statements of Operations
(In thousands, except per share data)

    Three months
ended September 30,
    Nine months
ended September 30,
    2019     2018     2019     2018  
Consolidated statements of operations:                                
Net sales   $ 683     $ 151     $ 1,715     $ 625  
Cost of goods sold     354       97       766       387  
Gross profit     329       54       949       239  
Operating expenses:                                
Research and development     2,275       2,333       8,279       9,007  
Selling, general and administrative     8,143       11,272       28,156       30,105  
Restructuring and other severance related charges     805       -       1,997       -  
Total operating expenses     11,223       13,606       38,432       39,111  
Loss from operations     (10,894 )     (13,552 )     (37,483 )     (38,872 )
Other income/(expense)                                
Change in fair value of warrant liability     -       -       -       (1,871 )
Interest and other income, net     206       355       850       580  
Other expense     -       (5 )     (17 )     (264 )
Total other income/(expense)     206       350       833       (1,555 )
Loss before income taxes     (10,688 )     (13,202 )     (36,650 )     (40,427 )
Provision for income taxes     -      
View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at